NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Journal Article (Journal Article)
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
- Zelenetz, AD; Gordon, LI; Chang, JE; Christian, B; Abramson, JS; Advani, RH; Bartlett, NL; Budde, LE; Caimi, PF; De Vos, S; Dholaria, B; Fakhri, B; Fayad, LE; Glenn, MJ; Habermann, TM; Hernandez-Ilizaliturri, F; Hsi, E; Hu, B; Kaminski, MS; Kelsey, CR; Khan, N; Krivacic, S; LaCasce, AS; Lim, M; Narkhede, M; Rabinovitch, R; Ramakrishnan, P; Reid, E; Roberts, KB; Saeed, H; Smith, SD; Svoboda, J; Swinnen, LJ; Tuscano, J; Vose, JM; Dwyer, MA; Sundar, H
- November 2021
Volume / Issue
- 19 / 11
Start / End Page
- 1218 - 1230
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States